정밀한 천식 치료를 위한 생물학적 제제

키워드

참고문헌 (76)

1. Wurth M, "factors associated with asthma development and control in children. Mouse infestation, antipyretics, respiratory viruses, and allergic sensitization", Am J Respir Crit Care Med, 196, pp.1605~1607 (2017)
2. Masoli M, "The global burden of asthma: executive summary of the GINA Dissemination Committee report", Allergy, 59, pp.469~478 (2004)
3. Kim BK, "Allergies are still on the rise? A 6-year nationwide population-based study in Korea", Allergol Int, 65, pp.186~191 (2016)
4. Pelaia G, "The potential of biologics for the treatment of asthma", Nat Rev Drug Discov, 11, pp.958~972 (2012)
5. Sokol CL, "A mechanism for the initiation of allergen-induced T helper type 2 responses", Nat Immunol, 9, pp.310~318 (2008)
6. Brusselle GG, "Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma", Nat Med, 19, pp.977~979 (2013)
7. Davies DE, "Airway remodeling in asthma: new insights", J Allergy Clin Immunol, 111, pp.215~225 (2003)
8. Lötvall J, "Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome", J Allergy Clin Immunol, 127, pp.355~360 (2011)
9. Tabatabaian F, "Biologic and new therapies in asthma", Immunol Allergy Clin North Am, 37, pp.329~343 (2017)
10. Katial RK, "Changing paradigms in the treatment of severe asthma: the role of biologic therapies", J Allergy Clin Immunol Pract, 5, pp.S1~S14 (2017)
11. Wenzel SE, "Asthma phenotypes: the evolution from clinical to molecular approaches", Nat Med, 18, pp.716~725 (2012)
12. Kuhl K, "Targeting IgE in asthma", Curr Opin Pulm Med, 18, pp.1~5 (2012)
13. Busse W, "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma", J Allergy Clin Immunol, 108, pp.184~190 (2001)
14. Fahy JV, "The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects", Am J Respir Crit Care Med, 155, pp.1828~1834 (1997)
15. Humbert M, "Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE", Allergy, 60, pp.309~316 (2005)
16. Normansell R, "Omalizumab for asthma in adults and children", Cochrane Database Syst Rev, pp.CD003559~ (2014)
17. Bousquet J, "The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma", Allergy, 60, pp.302~308 (2005)
18. Brusselle G, ""Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study", Respir Med, 103, pp.1633~1642 (2009)
19. Braunstahl GJ, "The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma", Respir Med, 107, pp.1141~1151 (2013)
20. Humbert M, "Omalizumab in asthma: an update on recent developments", J Allergy Clin Immunol Pract, 2, pp.525~536 (2014)
21. Busse W, "High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects", J Allergy Clin Immunol, 132, pp.485~486 (2013)
22. Lanier B, "Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma", J Allergy Clin Immunol, 124, pp.1210~1216 (2009)
23. Corren J, "Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma", J Allergy Clin Immunol, 111, pp.87~90 (2003)
24. Busse W, "Omalizumab and the risk of malignancy: results from a pooled analysis", J Allergy Clin Immunol, 129, pp.983~989 (2012)
25. Long A, "Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab", J Allergy Clin Immunol, 134, pp.560~567 (2014)
26. Cox L, "American Academy of Allergy, Asthma & Immunology", American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report, 2011, pp.128, 210~212
27. Green RH, "Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial", Lancet, 360, pp.1715~1721 (2002)
28. Jayaram L, "Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations", Eur Respir J, 27, pp.483~494 (2006)
29. Chlumský J, "Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma", J Int Med Res, 34, pp.129~139 (2006)
30. Takatsu K, "IL-5 and eosinophilia", Curr Opin Immunol, 20, pp.288~294 (2008)
31. Shardonofsky FR, "Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma", J Allergy Clin Immunol, 104, pp.215~221 (1999)
32. Flood-Page P, "Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics", J Clin Invest, 112, pp.1029~1036 (2003)
33. Menzies-Gow A, "Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics", J Allergy Clin Immunol, 111, pp.714~719 (2003)
34. Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia", N Engl J Med, 360, pp.985~993 (2009)
35. Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma", N Engl J Med, 360, pp.973~984 (2009)
36. Pavord ID, "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
37. Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)
38. Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma", N Engl J Med, 371, pp.1189~1197 (2014)
39. Haldar P, "Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis", J Allergy Clin Immunol, 133, pp.921~923 (2014)
40. Castro M, "Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study", Am J Respir Crit Care Med, 184, pp.1125~1132 (2011)
41. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir Med, 3, pp.355~366 (2015)
42. Corren J, "Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts", Chest, 150, pp.799~810 (2016)
43. Bjermer L, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study", Chest, 150, pp.789~798 (2016)
44. Ghazi A, "Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma", Expert Opin Biol Ther, 12, pp.113~118 (2012)
45. Busse WW, "Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma", J Allergy Clin Immunol, 125, pp.1237~1244 (2010)
46. Laviolette M, "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia", J Allergy Clin Immunol, 132, pp.1086~1096 (2013)
47. Castro M, "Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study", Lancet Respir Med, 2, pp.879~890 (2014)
48. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
49. Nair P, "Oral Glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
50. Blanchard C, "Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)", Clin Exp Allergy, 35, pp.1096~1103 (2005)
51. Corren J, "Lebrikizumab treatment in adults with asthma", N Engl J Med, 365, pp.1088~1098 (2011)
52. Wenzel S, "Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies", Lancet, 370, pp.1422~1431 (2007)
53. Slager RE, "IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist", J Allergy Clin Immunol, 130, pp.516~522 (2012)
54. Hanania NA, "Lebrikizumab in moderate-to-severe asthma:9 pooled data from two randomised placebo-controlled studies", Thorax, 70, pp.748~756 (2015)
55. Hanania NA, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials", Lancet Respir Med, 4, pp.781~796 (2016)
56. Piper E, "A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma", Eur Respir J, 41, pp.330~338 (2013)
57. Brightling CE, "Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial", Lancet Respir Med, 3, pp.692~701 (2015)
58. Panettieri RA Jr, "Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program", Immunotherapy, 10, pp.473~490 (2018)
59. Tomkinson A, "Inhaled vs subcutaneous effects of a dual IL-4", IL-13 antagonist in a monkey model of asthma, 2010, pp.65, 69~77
60. Otulana BA, "phase 2b study of inhaled pitrakinra, an IL-4", IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. D101, 2011, pp.183, A6179~
61. Wenzel S, "Dupilumab in persistent asthma with elevated eosinophil levels", N Engl J Med, 368, pp.2455~2466 (2013)
62. Wenzel S, "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial", Lancet, 388, pp.31~44 (2016)
63. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 375, pp.2335~2348 (2016)
64. Simpson EL, "Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)", J Am Acad Dermatol, 75, pp.506~515 (2016)
65. Blauvelt A, "Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial", Lancet, 389, pp.2287~2303 (2017)
66. Bachert C, "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial", JAMA, 315, pp.469~479 (2016)
67. Gonem S, "Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial", Lancet Respir Med, 4, pp.699~707 (2016)
68. Erpenbeck VJ, "The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma", Pulm Pharmacol Ther, 39, pp.54~63 (2016)
69. Holgate ST, "Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial", Eur Respir J, 37, pp.1352~1359 (2011)
70. Wenzel SE, "A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma", Am J Respir Crit Care Med, 179, pp.549~558 (2009)
71. Ying S, "Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity", J Immunol, 174, pp.8183~8190 (2005)
73. Oh CK, "A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma", Respir Res, 14, pp.93~ (2013)
74. Busse WW, "Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial", Am J Respir Crit Care Med, 178, pp.1002~1008 (2008)
75. Kon OM, "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma", Lancet, 352, pp.1109~1113 (1998)
76. Busse WW, "Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma", Am J Respir Crit Care Med, 188, pp.1294~1302 (2013)

관련 논문AI추천